{"name":"Sumitomo Pharma America, Inc.","slug":"sumitomo-pharma-america-inc","ticker":"","exchange":"","domain":"sumitomopharmaamerica.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"azoles Phase 3 readout (Anesthesia, Propofol Adverse Reaction)","drug":"azoles","drugSlug":"azoles","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"Formoterol 12 ųg BID","genericName":"Formoterol 12 ųg BID","slug":"formoterol-12-g-bid","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Salmeterol MDI","genericName":"Salmeterol MDI","slug":"salmeterol-mdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Arformoterol 25 ųg BID","genericName":"Arformoterol 25 ųg BID","slug":"arformoterol-25-g-bid","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Arformoterol Tartrate Inhalation Solution","genericName":"Arformoterol Tartrate Inhalation Solution","slug":"arformoterol-tartrate-inhalation-solution","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"},{"name":"Levalbuterol HCl Inhalation Solution","genericName":"Levalbuterol HCl Inhalation Solution","slug":"levalbuterol-hcl-inhalation-solution","indication":"Acute bronchospasm in patients with reversible obstructive airway disease","status":"phase_3"},{"name":"Levalbuterol UDV TID","genericName":"Levalbuterol UDV TID","slug":"levalbuterol-udv-tid","indication":"Asthma maintenance and acute bronchospasm relief","status":"phase_3"},{"name":"Levalbuterol tartrate HFA MDI","genericName":"Levalbuterol tartrate HFA MDI","slug":"levalbuterol-tartrate-hfa-mdi","indication":"Acute bronchospasm in patients with reversible obstructive airway disease","status":"phase_3"},{"name":"Placebo plus Dexamethasone HFA","genericName":"Placebo plus Dexamethasone HFA","slug":"placebo-plus-dexamethasone-hfa","indication":"Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation","status":"phase_3"},{"name":"Racemic Albuterol","genericName":"Racemic Albuterol","slug":"racemic-albuterol","indication":"Acute bronchospasm relief in asthma","status":"phase_3"},{"name":"levalbuterol tartrate MDI","genericName":"levalbuterol tartrate MDI","slug":"levalbuterol-tartrate-mdi","indication":"Maintenance and relief of bronchospasm in asthma and in COPD","status":"phase_3"},{"name":"racemic albuterol MDI","genericName":"racemic albuterol MDI","slug":"racemic-albuterol-mdi","indication":"Acute bronchospasm relief in asthma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"AC-3933","genericName":"AC-3933","slug":"ac-3933","indication":"Other","status":"phase_2"},{"name":"Arformoterol and Tiotropium","genericName":"Arformoterol and Tiotropium","slug":"arformoterol-and-tiotropium","indication":"Other","status":"marketed"},{"name":"Eszopiclone (Lunesta)","genericName":"Eszopiclone (Lunesta)","slug":"eszopiclone-lunesta","indication":"Insomnia (sleep onset and sleep maintenance)","status":"marketed"},{"name":"Nusivertib","genericName":"Nusivertib","slug":"nusivertib","indication":"Other","status":"phase_1"},{"name":"azoles","genericName":"azoles","slug":"azoles","indication":"Other","status":"phase_1"},{"name":"ciclesonide nasal aerosol","genericName":"ciclesonide nasal aerosol","slug":"ciclesonide-nasal-aerosol","indication":"Allergic rhinitis","status":"marketed"},{"name":"mometasone nasal inhalation","genericName":"mometasone nasal inhalation","slug":"mometasone-nasal-inhalation","indication":"Allergic rhinitis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"APL-130277","genericName":"APL-130277","slug":"apl-130277","indication":"Parkinson's disease, acute OFF episodes","status":"phase_3"},{"name":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","genericName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","slug":"lurasidone-20-40-60-80-mg-flexibly-dosed","indication":"Schizophrenia","status":"phase_3"},{"name":"Lurasidone HC1","genericName":"Lurasidone HC1","slug":"lurasidone-hc1","indication":"Schizophrenia","status":"phase_3"},{"name":"subcutaneous apomorphine","genericName":"subcutaneous apomorphine","slug":"subcutaneous-apomorphine","indication":"Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APO-go","genericName":"APO-go","slug":"apo-go","indication":"Treatment of iron deficiency anemia","status":"phase_2"}]}],"pipeline":[{"name":"APO-go","genericName":"APO-go","slug":"apo-go","phase":"phase_2","mechanism":"APO-go is a medication used to treat iron deficiency anemia.","indications":["Treatment of iron deficiency anemia"],"catalyst":""},{"name":"Formoterol 12 ųg BID","genericName":"Formoterol 12 ųg BID","slug":"formoterol-12-g-bid","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Salmeterol MDI","genericName":"Salmeterol MDI","slug":"salmeterol-mdi","phase":"phase_3","mechanism":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"AC-3933","genericName":"AC-3933","slug":"ac-3933","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APL-130277","genericName":"APL-130277","slug":"apl-130277","phase":"phase_3","mechanism":"APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.","indications":["Parkinson's disease, acute OFF episodes"],"catalyst":""},{"name":"Arformoterol 25 ųg BID","genericName":"Arformoterol 25 ųg BID","slug":"arformoterol-25-g-bid","phase":"phase_3","mechanism":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy"],"catalyst":""},{"name":"Arformoterol Tartrate Inhalation Solution","genericName":"Arformoterol Tartrate Inhalation Solution","slug":"arformoterol-tartrate-inhalation-solution","phase":"marketed","mechanism":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment","Asthma maintenance treatment"],"catalyst":""},{"name":"Arformoterol and Tiotropium","genericName":"Arformoterol and Tiotropium","slug":"arformoterol-and-tiotropium","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eszopiclone (Lunesta)","genericName":"Eszopiclone (Lunesta)","slug":"eszopiclone-lunesta","phase":"marketed","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia (sleep onset and sleep maintenance)"],"catalyst":""},{"name":"Levalbuterol HCl Inhalation Solution","genericName":"Levalbuterol HCl Inhalation Solution","slug":"levalbuterol-hcl-inhalation-solution","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm in patients with reversible obstructive airway disease","Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Levalbuterol UDV TID","genericName":"Levalbuterol UDV TID","slug":"levalbuterol-udv-tid","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease.","indications":["Asthma maintenance and acute bronchospasm relief","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Levalbuterol tartrate HFA MDI","genericName":"Levalbuterol tartrate HFA MDI","slug":"levalbuterol-tartrate-hfa-mdi","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm in patients with reversible obstructive airway disease","Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","genericName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","slug":"lurasidone-20-40-60-80-mg-flexibly-dosed","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression"],"catalyst":""},{"name":"Lurasidone HC1","genericName":"Lurasidone HC1","slug":"lurasidone-hc1","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Nusivertib","genericName":"Nusivertib","slug":"nusivertib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo plus Dexamethasone HFA","genericName":"Placebo plus Dexamethasone HFA","slug":"placebo-plus-dexamethasone-hfa","phase":"phase_3","mechanism":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation"],"catalyst":""},{"name":"Racemic Albuterol","genericName":"Racemic Albuterol","slug":"racemic-albuterol","phase":"phase_3","mechanism":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm relief in asthma","Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"azoles","genericName":"azoles","slug":"azoles","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ciclesonide nasal aerosol","genericName":"ciclesonide nasal aerosol","slug":"ciclesonide-nasal-aerosol","phase":"marketed","mechanism":"Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Allergic rhinitis","Nasal polyps (in some formulations/regions)"],"catalyst":""},{"name":"levalbuterol tartrate MDI","genericName":"levalbuterol tartrate MDI","slug":"levalbuterol-tartrate-mdi","phase":"phase_3","mechanism":"Levalbuterol tartrate is a long-acting beta2-adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.","indications":["Maintenance and relief of bronchospasm in asthma and in COPD"],"catalyst":""},{"name":"mometasone nasal inhalation","genericName":"mometasone nasal inhalation","slug":"mometasone-nasal-inhalation","phase":"phase_3","mechanism":"Mometasone is a corticosteroid that works by inhibiting the release of pro-inflammatory cytokines and mediators.","indications":["Allergic rhinitis","Chronic rhinitis"],"catalyst":""},{"name":"racemic albuterol MDI","genericName":"racemic albuterol MDI","slug":"racemic-albuterol-mdi","phase":"phase_3","mechanism":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases.","indications":["Acute bronchospasm relief in asthma","Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief"],"catalyst":""},{"name":"subcutaneous apomorphine","genericName":"subcutaneous apomorphine","slug":"subcutaneous-apomorphine","phase":"phase_3","mechanism":"Subcutaneous apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to rapidly relieve motor symptoms of Parkinson's disease.","indications":["Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-08","type":"pipeline","source":"simplywall.st","summary":"Is Sumitomo Pharma (TSE:4506) Quietly Recasting Its Investment Story Around Regenerative Medicine And GEMTESA? - simplywall.st","headline":"Is Sumitomo Pharma (TSE:4506) Quietly Recasting Its Investment Story Around Regenerative Medicine And GEMTESA?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOaUN5S0VmenpvMzYyN2ItZEM2UGw4VTBpdlNHZk02NEFMX2RNX0diVExQODBURGVBeURxZWp6TDdVb1BhcFpnZG5FTlZnYXlJSlJJU21pbFNQWV9GWXN2Y1hlRWtpQWpYTm1FZk4wbEpkMUhZb1NoZkhQWkhzUVJ3WHROdE4xRFVDZUJocTlUTHJnd3VmZW11cjB2V0FUbjR6X0lVWkFtalRwaXFNVjdEU2dyMmdkSXBwNHBxTll2aXk0dGZVdmhnZUs1SVNYWm1mVjdZ?oc=5","date":"2026-03-01","type":"earnings","source":"TipRanks","summary":"Sumitomo Pharma Lifts Full-Year Profit Outlook on Strong GEMTESA Sales and Weaker Yen - TipRanks","headline":"Sumitomo Pharma Lifts Full-Year Profit Outlook on Strong GEMTESA Sales and Weaker Yen","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPQjVBeGZOQ2pTalZiY2tITDVlUWtVTC1YcnAzZ05Sd2Npclc3SUR1MGJMa2QtRFNKZFNVTlZzRzVQZXYzTTBHWTJKaHNRZTNNV01LcjAtTXNDWGxkUV9mQjA4NTBsOFZmR1NMRjNjMnVZeUR2aWRIbnI3bllpaGxWMDdkTFlOSWdMLWt2QlYyak1HUkUycHZaZEZJQXlSa1NDZXVERklzLVNxdHhBZVhXQk93VTBleGpXVmkxenRaNlppTzd6TXZLaDdNTThxcURPNG1kbTVlbDFUREs1UnpScmZfWHJGbFJvSWpkaWhrT2QtQlFuR3BvX1RGbmM5VnZNN3dr?oc=5","date":"2025-11-03","type":"regulatory","source":"PR Newswire","summary":"Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting - PR Newswire","headline":"Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOTmc1VDlPMXo3NExRT2p4OFFxQjU5d3NWZ3lLdEVIajJPQ2k4ZlFsVkhoR0JFbWlmajIwTWN5ZnVlcDhieTlUVUxHZFI0RDE5cjN1dy1PcU1pdFVVcldxb2ZlaVVQb1ZnZ1VxQ3BJY0NtaEM2VEo4MzBkMkNIbFBieDRfeG1OVFpRaXkxVnFQM0FPbXlKcmVyLTFrd2JfenBZUnNSVlJR?oc=5","date":"2025-10-17","type":"regulatory","source":"lupin.com","summary":"Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets - lupin.com","headline":"Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOYlJ6NFB3RHF3bEZjSlNqZ3pXalZsdjlkRXdvU2xDX0dsOXdhc29SaXVJWXpvUS11RmpoNTMtZmtrX3lNdnBWeHZ2QzBFT3F2UWdUUU5pN0Y5MGZJeGg3bklraGQ3Y2RuLUtRVFZqT0lsQ21uZWVyNkRteHQ2LVFjeFNLcEFxaVVfQWh0WDh0bGlZdm44eGlCLXpMYXVrQWhxcEc4cTZVZGU0bDVOX0lEVkdYQ0NQaFotYWNVYnFCVnNLREVlMU9Ud1Q4Q0FyZjNWeHoxRmZyWnBaZGpyN0NXcThYNHoyVFVsY3pGcTRxQmZjLUs0eTFxZTRaS09UZi14d3V1YlI0WExPWEU4bW1rdlVqUmN3RTFjME5EUDJfVjNRaUtxVWZVZlhsY25yZGhvTzNJeHhXWTlLUmtaSFE?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis - PR Newswire","headline":"Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQY1ljOF9JbjZxdzd3ZWljSUZsT0JZM1dVSkdwY2JlZWQ4Q1NXUDE0b1NLN29qREdUSm1SX2d6UHlVSGxYa1p4QUtJSG15T085YUY4WHRaNnZsZFJ5ekZfcmpValJoUkFSbFl4dEREaE8zdEE5U1hxZFhyMENUWjVrTVhpY2MxLTk4TlJuWW1HUXlYY2s?oc=5","date":"2025-07-01","type":"pipeline","source":"Fierce Pharma","summary":"Power couple Peetes team up to promote Sumitomo’s Gemtesa - Fierce Pharma","headline":"Power couple Peetes team up to promote Sumitomo’s Gemtesa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQYm9sR0FJN2xmckEwWmxfcXRXMDV5OXE2bXpVT2JoeG5NSmZBTmlHMGNQblYwUGNOcXlwaVk2aF9xYmstSUJ3bDExdHBCakx0Wk1jQUJhbDB6OVctZG9CS2s1aG1SSnAteC03Q0hacFRCcC1GY1E5SnF5VU83MEdzTVBHRXRCaDM3SUtzZW02OW9vYkNqc3AyYl9HYWlmNmhhTUdWQ2U3QTA1RXBHdnJ0ZzJuT0NJUXo1d1YzS2NCcVBNX0RyU0l0cTBremw3dkwxVnh3LW5UWmxiWlZmWFpuQXRla0pDVWoyX2daTHc4andQaUlVd3hxck1IR29rRWtLTGZsQnJ3bDRjel9kZVhRRF81b1o2ckJ3Q1k3dzJ6NTFGUFAzZnltR3N6aV9pTFoxc2dGUDJKdWtsXzZjYUZqZA?oc=5","date":"2025-06-30","type":"earnings","source":"PR Newswire","summary":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA® - PR Newswire","headline":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPZ2RFTHRNTXE2ckxVdVp3Ulpmbm1mZkJaZEF1Z0dzcWotOTdyWGtKajZnZnBSd09yLXJhU1BIMzZLUmFtNnBoNTluSHpuTW1zaWltNi1mcURKUnl0WmtTdHF0U3JxMEVlRWRWYXlLdm9FRHl4RW5XVXVhM1R2cDhQWS1xTzM1SVFObVpFSkswX2R6cERlNllBZzVzcnAyeUk4eU9TREgyQTYzVkE3UzdBdHJxWXk?oc=5","date":"2025-06-16","type":"regulatory","source":"Docwire News","summary":"FDA Issues Fast Track Designation to Oral PIM1 Kinase Inhibitor for Myelofibrosis - Docwire News","headline":"FDA Issues Fast Track Designation to Oral PIM1 Kinase Inhibitor for Myelofibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPMDJ3M2ZrOUZSeHRvYm9LYVBKS2UxN2htUWhjVTNHOEV5TnlBdkgtUXNkVFIxN0NoSm9xOUs5WDI2b0syeWZ1QWk0bHhUOEFLUEotRERoS1BKTXVKT2lpYm1RcVJoR1Ita2U4QU40d1pUTjg5bDN5RDFRVDhXdjNlN1NkdkVPM1pBWjlWNkZMMnEzejh3QXBHSTZUZzR5WGhXZkFQLWI3cnI0UTVxZERtcWhqSVE?oc=5","date":"2025-06-09","type":"pipeline","source":"The Pharma Letter","summary":"Knight Therapeutics gains rights to Sumitomo Pharma products in Canada - The Pharma Letter","headline":"Knight Therapeutics gains rights to Sumitomo Pharma products in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQeXVOdHVmU1U2cFRGZ0xWM3hVQ2hERkItUDR1TVJHOC02Wkh2T3NkWXZhRk1UZ2lxN05Wc0R6NnlyM2d6OVdhZC1rcVYxV0hZcldWeEtON1l0T2VFc2xDZngwUTl4X0RNUS1UbnNFTExYdzlGQ3E3QnZKUjlBcVNXUjc3M0g4NjRHaVAyWkxIbHBBOGVILU9RaThINUFvOERieXpUTFZ0ek9SQVk4RkExUXN3ZmtPSVFnUTAyNVEweGxRcVBoNHh4QnYyZTJvaGZBUUQ0R1dTSnlTWm5HRFI5MmRYamd2NzQwRnNlQVN0SDJEQzRDVDNCbFhDZi1RQzVOTnNvY29PQ3hZcDFfZUhVMnVZSm0tOG5wcldXQzVOLV9sMmFqdC0w?oc=5","date":"2025-06-05","type":"pipeline","source":"globenewswire.com","summary":"Knight Therapeutics and Sumitomo Pharma enter into - globenewswire.com","headline":"Knight Therapeutics and Sumitomo Pharma enter into","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNQm96S29fOUswTHRwa2NQd2tmcmhNVDlBR0xrQk1ud1JHdFI4QnRIbGZZRnRNdjhub1NVZ0VtR2s0bEMyYU9WRjdHTzNYVHp0VFZBVndOSEVCUUhzN1pVVGhBY1liQjNnZ29PMU9USmRmTE9jWGJBSTdQWjJlUkcxWXBFTU5pampkOEdOc1lmWQ?oc=5","date":"2024-08-05","type":"pipeline","source":"Worcester Business Journal","summary":"Marlborough biotech company set to lay off 50+ employees - Worcester Business Journal","headline":"Marlborough biotech company set to lay off 50+ employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdkFVcHN3M0pPN21QaWVGem4zOFdwUU9HajRlaU9SQ0gwUTMxQWtZY3hOMHFfVTFXa0dWTFppY3RHUlZzeGNHOFAzY3BXTmQ5U3JjN252akROMGdHTHhLWnhVdndyQ0k5QUNjbWZPUmhVeklTSzhnUGZ5VkJaWlZtV0lqWmZQUW1oMVRZcUNBd2syUmdqWVRYOFotOVlNRUtiUkhqeERJdnQyTVk?oc=5","date":"2023-04-03","type":"pipeline","source":"Fierce Biotech","summary":"Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning - Fierce Biotech","headline":"Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning","sentiment":"neutral"}],"patents":[],"drugCount":23,"phaseCounts":{"phase_2":2,"phase_3":15,"marketed":4,"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}